OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts discuss strategies for optimizing first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.
September 30th 2021
Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.
Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.
October 7th 2021
Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.
A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.
October 14th 2021
In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.
Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.
October 21st 2021
Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.
After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.